Risankizumab: Mechanism of action, clinical and translational science
Clinical and Translational ScienceRisankizumab is a high‐affinity neutralizing anti‐interleukin (IL)‐23 monoclonal antibody marketed in over 40 countries across the globe to treat several inflammatory diseases, such as plaque psoriasis (PsO), psoriatic arthritis (PsA), and Crohn's ...
Yinuo Pang +5 more
doaj +2 more sources
Risankizumab in severe asthma - A phase 2a, placebo-controlled trial [PDF]
, 2021 Background: Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear ...
Brightling, Christopher
core +9 more sources
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date [PDF]
Psoriasis: Targets and Therapy, 2018 Álvaro Machado,1 Tiago Torres1,2 1Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal Abstract: Psoriasis is
Machado Á, Torres T
doaj +3 more sources
Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children
Dermatology and Therapy, 2023 Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease that affects men and women of all ages, including children. PRP is characterized by follicular and palmoplantar hyperkeratosis and salmon-colored scaling plaques.
Marta Kołt-Kamińska +3 more
doaj +2 more sources
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials [PDF]
Rheumatology and TherapyIntroduction The ongoing KEEPsAKE 1 and 2 (KS1; KS2) trials evaluate the efficacy and safety of risankizumab in patients with psoriatic arthritis (PsA) who had an inadequate response to ≥ 1 conventional synthetic disease-modifying antirheumatic drug(s ...
Andrew Östör +15 more
doaj +2 more sources
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial [PDF]
Rheumatology and TherapyIntroduction Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had inadequate ...
Andrew Östör +13 more
doaj +2 more sources
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison [PDF]
Rheumatology and TherapyIntroduction The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD naïve) or with previous inadequate response or intolerance to tumor necrosis factor inhibitors ...
Philip J. Mease +8 more
doaj +2 more sources
Dermatology Practical & ConceptualIntroduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis. Objective: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two ...
Federico Pirro +21 more
doaj +2 more sources
Dermatology and TherapyIntroduction Despite advancements in the treatment of psoriasis (PsO), there are few head-to-head studies assessing comparative effectiveness of the newest therapies approved to treat PsO.
April W. Armstrong +5 more
doaj +2 more sources
Case Reports in GastroenterologyIntroduction: Treatment of Crohn’s disease (CD) and axial spondyloarthritis (axSpA) is challenging, with CD refractory to anti-TNF antibodies.
Anouk Lehmann +4 more
doaj +2 more sources